FILSUVEZ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Filsuvez, and what generic alternatives are available?
Filsuvez is a drug marketed by Chiesi and is included in one NDA. There are five patents protecting this drug.
This drug has eighty-six patent family members in thirty-three countries.
The generic ingredient in FILSUVEZ is birch triterpenes. Two suppliers are listed for this compound. Additional details are available on the birch triterpenes profile page.
DrugPatentWatch® Generic Entry Outlook for Filsuvez
Filsuvez will be eligible for patent challenges on December 18, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 18, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FILSUVEZ?
- What are the global sales for FILSUVEZ?
- What is Average Wholesale Price for FILSUVEZ?
Summary for FILSUVEZ
International Patents: | 86 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
What excipients (inactive ingredients) are in FILSUVEZ? | FILSUVEZ excipients list |
DailyMed Link: | FILSUVEZ at DailyMed |
![FILSUVEZ drug patent expirations Drug patent expirations by year for FILSUVEZ](/p/graph/s/t/FILSUVEZ-patent-expirations.png)
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for FILSUVEZ
Generic Entry Date for FILSUVEZ*:
Constraining patent/regulatory exclusivity:
TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA (EB) IN ADULT AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER NDA:
Dosage:
GEL;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for FILSUVEZ
FILSUVEZ is protected by five US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of FILSUVEZ is ⤷ Sign Up.
This potential generic entry date is based on TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA (EB) IN ADULT AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting FILSUVEZ
Betulin-containing birch bark extracts and their formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Betulin-containing birch bark extracts and their formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF BIRCH TRITERPENES FOR THE TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA
Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Use of an oleogel containing triterpene for healing wounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF BIRCH TRITERPENES FOR THE TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA
Use of an oleogel containing triterpene for healing wounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF BIRCH TRITERPENES FOR THE TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA
FDA Regulatory Exclusivity protecting FILSUVEZ
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA (EB) IN ADULT AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chiesi | FILSUVEZ | birch triterpenes | GEL;TOPICAL | 215064-001 | Dec 18, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Chiesi | FILSUVEZ | birch triterpenes | GEL;TOPICAL | 215064-001 | Dec 18, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Chiesi | FILSUVEZ | birch triterpenes | GEL;TOPICAL | 215064-001 | Dec 18, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for FILSUVEZ
See the table below for patents covering FILSUVEZ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2323082 | ⤷ Sign Up | |
Japan | 4468987 | ⤷ Sign Up | |
Japan | 2023168437 | ベツリン含有白樺樹皮抽出物およびその製剤 (BETULIN-CONTAINING BIRCH BARK EXTRACTS AND THEIR FORMULATION) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FILSUVEZ
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1758555 | 16C1003 | France | ⤷ Sign Up | PRODUCT NAME: BETULINE; REGISTRATION NO/DATE: EU/1/15/1069 20160118 |
1758555 | C201630042 | Spain | ⤷ Sign Up | PRODUCT NAME: BETULINA; NATIONAL AUTHORISATION NUMBER: EU/1/15/1069; DATE OF AUTHORISATION: 20160114; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1069; DATE OF FIRST AUTHORISATION IN EEA: 20160114 |
1758555 | C20160023 00332 | Estonia | ⤷ Sign Up | PRODUCT NAME: BETULIIN;REG NO/DATE: EU/1/15/1069 18.01.2016 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |